TL;DR: Growth hormone secretagogues (GHS) are research compounds studied for their ability to stimulate the pituitary to release endogenous GH. Two mechanistic families are covered in the peer-reviewed literature: GHRH analogs (sermorelin, CJC-1295, tesamorelin), which act on the GHRH receptor; and ghrelin-receptor agonists (ipamorelin, GHRP-6, GHRP-2), which act via GHS-R1a. Evidence tiers range from animal models to limited human trials. WADA prohibits the full class under S2. Tesamorelin holds one narrow FDA approval; most other compounds in this category are not approved for human use.
Research-Use Disclaimer: This article is for educational and research reference purposes only. The compounds discussed are research chemicals not approved by the FDA for general human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published peer-reviewed research. For adults 21+ with a research interest only.
What Is the Growth Hormone Axis and Why Do Researchers Study It?
The growth hormone / insulin-like growth factor-1 (GH/IGF-1) axis is the central endocrine signaling cascade that governs GH secretion and downstream anabolic and metabolic effects. Its components, hypothalamus, pituitary, liver, and peripheral tissues, interact through two primary regulatory signals: stimulatory input from growth hormone-releasing hormone (GHRH) and inhibitory input from somatostatin. Understanding this axis has driven decades of pharmaceutical research into compounds that can modulate GH output without directly administering recombinant GH.
How Does the GH/IGF-1 Axis Work?
Hypothalamic GHRH, a 44-amino acid peptide, is released in a pulsatile pattern and binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. This triggers GH synthesis and release. GH then acts on peripheral tissues, most importantly the liver, to stimulate IGF-1 production, which mediates many of GH’s downstream effects. Somatostatin, released by the periventricular nucleus of the hypothalamus, counteracts GHRH, creating the characteristic pulsatile pattern of GH secretion throughout the day.
A 2025 review by Dieguez, López, and Casanueva in Reviews in Endocrine & Metabolic Disorders provides a comprehensive summary of this architecture, noting that GHRH is “the primary regulator of pulsatile GH secretion, counteracted by somatostatin, ” and that the highest non-brain expression of the GHRH receptor is in pituitary somatotroph cells, where it directly targets GH production. (Source: PubMed, PMID 39913072.)
Where Does Ghrelin Fit Into the GH Axis?
Ghrelin, a 28-amino acid octanoylated peptide produced predominantly by the stomach, was identified in 1999 as the endogenous ligand for the GH secretagogue receptor type 1a (GHS-R1a). Its discovery formalized a second, distinct stimulatory pathway for GH release that operates in parallel with GHRH rather than through it. A 2010 review by Lanfranco et al. in Frontiers of Hormone Research described ghrelin’s dual mechanism: it stimulates GH release both directly on pituitary cells and through modulation of GHRH from the hypothalamus, with some functional anti-somatostatin activity also documented. (Source: PubMed, PMID 20616513.)
A 2014 review by Khatib et al. in the Journal of Clinical and Diagnostic Research further characterized this system, describing ghrelin as “a powerful pharmacological agent that exerts a potent, time-dependent stimulation of pulsatile secretion of GH” through the GHS-R1a receptor and IP3 signal transduction. (Source: PubMed, PMID 25302229.) The discovery of ghrelin, as the 2025 Dieguez review notes, “significantly advanced understanding of GH regulation” and established GHS-R1a agonism as a mechanistically independent target for GH research.
What Are the Two Main Families of GH Secretagogues Studied in the Literature?
Research on GH secretagogues divides into two mechanistic families based on their receptor targets. The table below summarizes the key distinctions documented in the peer-reviewed literature.
| Family | Receptor Target | Representative Compounds | Mechanism (simplified) | FDA Status Pattern |
|---|---|---|---|---|
| GHRH analogs | GHRH receptor (GHRHR) on pituitary somatotrophs | Sermorelin, CJC-1295, Tesamorelin | Mimic hypothalamic GHRH; stimulate GH synthesis and release via cAMP pathway | Tesamorelin: approved (HIV lipodystrophy, narrow indication). Sermorelin: previously approved, now limited. CJC-1295: not approved. |
| Ghrelin-receptor / GHS-R1a agonists | GHS-R1a (ghrelin receptor) on pituitary and hypothalamus | Ipamorelin, GHRP-6, GHRP-2 | Mimic ghrelin’s GHS-R1a signaling; stimulate GH release independently of GHRH; act synergistically with GHRH analogs | None currently approved for human use in this subcategory |
A key finding across the research literature is that these two families act synergistically. A 2009 review by Cordido et al. in Current Drug Discovery Technologies summarized multiple studies showing that GHS-R1a agonists stimulate GH release “via a separate pathway distinct from GHRH/somatostatin, ” and that co-administration with GHRH produces GH responses greater than either stimulus alone. (Source: PubMed, PMID 19275540.) This synergy is one reason researchers study the combination of GHRH-pathway and GHS-R1a-pathway compounds in parallel.
GHRH Analogs: What Does the Research Show?
GHRH analogs are peptides engineered to mimic or extend the action of endogenous GHRH, typically by modifying the native 44-amino acid sequence to improve stability, half-life, or receptor binding. The three most-studied compounds in this subcategory are sermorelin, tesamorelin, and CJC-1295. Each has its own compound post in this cluster, see the Related Reading section below. Brief summaries follow.
What Is Sermorelin and What Has the Research Documented?
Sermorelin is the acetate salt of GHRH(1-29)-NH₂, the biologically active N-terminal fragment of endogenous GHRH. It was among the earliest GHRH-pathway compounds studied in clinical contexts. A 1993 randomized controlled trial by Neyzi et al. in Acta Paediatrica Supplement compared GHRH(1-29)-NH₂ with recombinant GH in prepubertal children with GH deficiency of hypothalamic origin, documenting that high-dose GHRH(1-29)-NH₂ produced height velocity gains comparable to GH therapy, with a priming effect on the pituitary’s endogenous GHRH responsiveness during treatment. (Source: PubMed, PMID 8329826.) Sermorelin’s short plasma half-life (minutes) is a pharmacokinetic limitation noted throughout the literature. Read the compound profile: What Is Sermorelin?
What Is CJC-1295 and How Does Its Pharmacokinetics Differ?
CJC-1295 is a GHRH analog engineered with a drug-affinity complex (DAC) modification that covalently binds to albumin in plasma, dramatically extending its half-life compared to sermorelin. A 2006 randomized, double-blind, placebo-controlled trial by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism, one of the few published human CJC-1295 studies, reported that a single subcutaneous injection produced dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold lasting 6 or more days, and in mean IGF-I concentrations of 1.5- to 3-fold lasting 9–11 days, with an estimated half-life of 5.8–8.1 days. (Source: PubMed, PMID 16352683.) No serious adverse events were reported in that study. CJC-1295 is not FDA approved for any indication. Read the compound profile: What Is CJC-1295?
What Is Tesamorelin and What Is Its Regulatory Status?
Tesamorelin is a synthetic GHRH analog modified with a trans-3-hexenoic acid group at the N-terminus to improve stability. It holds the most advanced regulatory status of any compound in this category. A 2026 meta-analysis of five RCTs by Badran et al. in Obesity Research & Clinical Practice found that tesamorelin was associated with significant reductions in visceral adipose tissue (MD = −27.71 cm², 95% CI [−38.37, −17.06]), trunk fat, hepatic fat percentage, and waist circumference, alongside a significant increase in lean body mass and IGF-1 levels, without serious adverse effects or clinically significant glucose perturbation in HIV-associated lipodystrophy. (Source: PubMed, PMID 41545261.) This evidence base underpins the compound’s FDA approval (brand name Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, a narrow indication that does not extend to other populations or purposes. Read the compound profile: What Is Tesamorelin?
Ghrelin-Receptor Agonists (GHS-R1a): What Does the Research Show?
GH-releasing peptides (GHRPs) and related synthetic ghrelin mimetics act via the GHS-R1a receptor, the endogenous ghrelin receptor, to stimulate GH release through a mechanistically distinct pathway from GHRH. The best-characterized compound in this subcategory for GH-selectivity is ipamorelin.
What Is Ipamorelin and Why Does the Research Describe It as Selective?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk. A landmark 1998 study by Raun et al. in the European Journal of Endocrinology characterized ipamorelin as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH, ” noting that, unlike GHRP-6 and GHRP-2, ipamorelin did not release ACTH or cortisol at doses more than 200-fold above its GH-releasing ED₅₀ in swine models. (Source: PubMed, PMID 9849822.) This selectivity profile distinguishes ipamorelin from earlier GHRPs and is a key reason it is frequently cited in the GH secretagogue research literature.
A subsequent 1999 study by Johansen et al. in Growth Hormone & IGF Research extended ipamorelin’s preclinical profile by demonstrating that dose-dependent subcutaneous administration increased longitudinal bone growth rate in female rats from 42 to 52 µm/day, with significant effects on body weight gain, without affecting total IGF-I levels or serum bone formation markers. (Source: PubMed, PMID 10373343.) Ipamorelin has no current FDA approval. Read the compound profile: What Is Ipamorelin?
What Other GHS-R1a Agonists Appear in the Research Literature?
Beyond ipamorelin, the GHS-R1a agonist literature includes GHRP-6, GHRP-2, and the orally active MK-677 (ibutamoren). A 2009 review by Cordido et al. provides comparative context: GHRP-6 and GHRP-2 produce robust GH release but, unlike ipamorelin, also stimulate ACTH and cortisol secretion in preclinical and some human studies, which is characterized in the literature as a reduced selectivity profile. The review also summarizes evidence that ghrelin receptor antagonists have been investigated as potential anti-obesity agents, illustrating that GHS-R1a is a bidirectional pharmacological target in current research. None of these GHS-R1a agonists hold FDA approval for general use.
What Does the GH Axis Genetics Literature Add to the Research Context?
Foundational understanding of why GHRH-pathway compounds are pharmacologically interesting comes partly from genetic studies. A 2011 review by Mullis in Best Practice & Research: Clinical Endocrinology & Metabolism examined GHRH, GHRHR, GH, and GH-receptor gene variants, establishing that mutations affecting the GHRH-GH-IGF-I axis at any level, including the GHRH receptor, can produce GH deficiency phenotypes, demonstrating the causal role of each component in normal somatotroph function. (Source: PubMed, PMID 21396573.) This genetic evidence validates the axis’s architecture and clarifies why pharmacological interventions at the GHRH receptor level can influence downstream GH and IGF-1 output.
What Is the Evidence Tier Landscape for GH Secretagogues?
Across the GH secretagogue category, evidence tiers vary meaningfully between compounds. The following table reflects the state of peer-reviewed literature as of mid-2026.
| Compound | Family | Highest Evidence Level Available | FDA Status | WADA Status |
|---|---|---|---|---|
| Tesamorelin | GHRH analog | Human RCTs (HIV lipodystrophy indication) | Approved, Egrifta (narrow indication only) | Prohibited, S2 |
| Sermorelin | GHRH analog | Human clinical studies (GH deficiency in pediatric populations) | Previously approved; compounding-restricted as of FDA actions 2023 | Prohibited, S2 |
| CJC-1295 | GHRH analog | Limited human data (one published RCT in healthy adults) | Not approved | Prohibited, S2 |
| Ipamorelin | GHS-R1a agonist | Animal model data (rat, swine); no published human RCTs | Not approved | Prohibited, S2 |
| GHRP-6 | GHS-R1a agonist | Animal and some human pharmacodynamic studies | Not approved | Prohibited, S2 |
The key limitation to state plainly: Preclinical GH-stimulation findings, even in multiple species, do not confirm that the same compounds produce equivalent, safe, or therapeutically useful effects in humans at unsupervised doses. The human evidence base for most compounds in this category is thin, and the one compound with robust human RCT data (tesamorelin) was studied only in a specific immunocompromised population with a defined metabolic condition.
What Is the Regulatory Status of GH Secretagogues?
WADA: What Does Section S2 Cover?
The World Anti-Doping Agency’s Prohibited List includes GH secretagogues under Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This section explicitly prohibits “growth hormone secretagogues, e.g. ghrelin and ghrelin mimetics, e.g. anamorelin, ibutamoren/MK-677, lenomorelin; growth hormone-releasing factors, e.g. CJC-1295, sermorelin, tesamorelin.” The S2 prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules. This is distinct from the S0 (Non-Approved Substances) category applied to compounds like BPC-157, GH secretagogues receive a compound-specific S2 listing because WADA has specifically identified them as performance-relevant.
FDA: Mixed Status Across the Category
FDA status varies within this compound class. Tesamorelin (Egrifta) received FDA approval in November 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, the only current FDA approval in this category. Sermorelin had FDA approval for growth hormone deficiency diagnosis and treatment but has faced compounding restrictions. CJC-1295, ipamorelin, GHRP-6, and GHRP-2 have no approved indications and are not legally available as drugs or dietary supplements in the United States. Researchers should consult current FDA guidance for the regulatory status of any specific compound at time of study.
Frequently Asked Questions About GH Secretagogues
What is a growth hormone secretagogue?
A growth hormone secretagogue (GHS) is any compound that stimulates the pituitary gland to release endogenous growth hormone. The research literature describes two main mechanistic families: GHRH analogs, which bind the GHRH receptor on somatotroph cells to mimic the hypothalamic trigger for GH release; and ghrelin-receptor (GHS-R1a) agonists, which stimulate GH release via a separate, synergistic pathway. Neither family directly administers GH, they act upstream in the GH/IGF-1 axis.
Are GH secretagogues banned by WADA?
Yes. WADA prohibits GH secretagogues under Section S2 of the Prohibited List, which covers “Peptide Hormones, Growth Factors, Related Substances, and Mimetics.” This prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules, and explicitly names GHRH analogs, ghrelin mimetics, and GH-releasing peptides.
Is tesamorelin FDA approved?
Yes, with a narrow indication. Tesamorelin (Egrifta) was approved by the FDA in 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. This approval does not extend to body composition enhancement, anti-aging, or other indications. All other GHRH analogs and all GHS-R1a agonists studied in the research literature are not FDA approved.
What is the difference between GHRH analogs and ghrelin-receptor agonists?
GHRH analogs (sermorelin, CJC-1295, tesamorelin) bind the GHRH receptor on pituitary somatotrophs, mimicking the hypothalamic signal to trigger GH synthesis and release via the cAMP pathway. Ghrelin-receptor agonists (ipamorelin, GHRP-6, GHRP-2) act via GHS-R1a through a distinct intracellular signaling cascade. Research shows these two families are synergistic: combined administration in preclinical models produces GH release greater than either agent alone, because they converge on the somatotroph via separate mechanisms.
Research use only. Not intended for human use. Not FDA approved (except tesamorelin for its specific narrow indication). This article documents published scientific literature for educational and reference purposes only and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources via PubMed, read them in full. Must be 21+.